U.S. Department of War provides $3.7M for Armata Pharmaceuticals' AP-SA02 program

Armata Pharmaceuticals announced it received an additional $3.7 million in non-dilutive funds from the U.S. Department of War on September 23, 2026. This funding supports the Phase 3 development of AP-SA02, a therapeutic targeting *Staphylococcus aureus* bacteremia. The total non-dilutive U.S. Department of War funding for the AP-SA02 program is now approximately $32.4 million, following a previous award of $28.7 million. The funds were provided through the Medical Technology Enterprise Consortium and managed by the Naval Medical Research Command.

The funding supports Armata Pharmaceuticals, a late clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics. This government investment underscores continued interest in advancing the AP-SA02 program for difficult-to-treat, antibiotic-resistant bacterial infections.